Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil Assessed by 24-Hour Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension

Abstract

Olmesartan medoxomil reduced daytime and 24-hour DBP and SBP, assessed by ABPM, more effectively than candesartan cilexetil at the doses tested. The majority of the treatment effect in both groups was seen after only 1 or 2 weeks of dosing, when the between-group differences were already statistically significant.

Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension

“…13 Such findings are inline with in vitro studies, which show that OM produces a strong blockade of the AT 1 receptor, with a high degree of insurmountable binding, slow dissociation and high affinity for the AT 1 receptor. 14 The clinical consequences of this robust inhibition of the AT 1 receptor appear as the sustained reductions in SBP and DBP over 24 h seen in the metaanalysis of Fabia et al 7 Direct clinical comparisons in which OM produced larger reductions in BP measured by ABPM than several other ARBs may also reflect stronger AT 1 receptor blockade [15][16][17] The 2009 re-appraisal of the ESH-ESC guidelines on hypertension management acknowledge that, in general, in up to 20% of patients with hypertension BP control cannot be achieved by a two-drug combination. 4 However, even treatment with an ARB with superior AT 1 receptor binding characteristics may not lead to high rates of BP goal achievement in a population that includes a high proportion of patients with severe hypertension.…”

Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods

“…ARB is known not only to lower blood pressure but also to repress vascular injury [27]. The benefits of olmesartan include significant reductions in both diastolic and systolic blood pressure, superior efficacy relative to all other ARBs with which it has been compared, high responder rates, a rapid onset of action, and a similar safety profile to placebo [28]. In addition, blockade of the angiotensin II receptor has other beneficial effects on the kidney.…”

Sartans: differences, similitudes and costs

“…Entrambi i trattamenti hanno ridotto il livello plasmatico dell'antigene dell'inibitore 1 dell'attivatore del plasminogeno, la trombomodulina, il fibrinogeno e hanno aumentato il livello sierico dell'antigene dell'inibitore dell'attivatore tissutale del plasminogeno, anche se eprosartan in misura maggiore [33]. Probabilmente la causa di tali differenze è da attribuire ai diversi dosaggi con cui sono stati somministrati i farmaci nei diversi trial.…”